Emmessar Biotech & Nutrition Ltd Stock Price Today (NSE: EMMESSA)
Fundamental Score
Emmessar Biotech & Nutrition Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Emmessar Biotech & Nutrition Ltd share price today is ₹27.02, up +0.00% on NSE/BSE as of 17 February 2026. Emmessar Biotech & Nutrition Ltd (EMMESSA) is a Small-cap company in the Commodity Chemicals sector with a market capitalisation of ₹15.95 (Cr). The 52-week high for EMMESSA share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 69.37x, EMMESSA is currently trading above its industry average P/E of 20.98x. The company has a Return on Equity (ROE) of 4.23% and a debt-to-equity ratio of 0.00.
Emmessar Biotech & Nutrition Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Emmessar Biotech & Nutrition Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Emmessar Biotech & Nutrition Share Price: A ROCE Efficiency Analysis
A crucial, often overlooked dynamic in the commodity chemicals sector is the 'margin squeeze' – the relentless pressure on profitability due to fluctuating raw material costs and intense competition. In this context, understanding the Return on Capital Employed (ROCE) becomes paramount. This analysis examines the Emmessar Biotech & Nutrition share price, currently trading at ₹27.4, through the lens of ROCE efficiency.
Emmessar Biotech & Nutrition Ltd. currently trades at a Price-to-Earnings (PE) ratio of 69.37. More critically, their ROCE stands at 12.61%. ROCE measures how efficiently a company is generating profits from its capital employed. This metric is a vital indicator of a company's ability to create value for its shareholders. However, its PE looks unfavorable when compared with the industry.
Considering peer comparisons, we can juxtapose Emmessar Biotech & Nutrition Ltd with
AG Ventures. While both operate in the same sector, anecdotal evidence suggests a potential disparity in management quality, influencing capital allocation decisions. For instance, differences in inventory management or strategic investments could directly affect ROCE performance between the two companies. While we won't speak on AG Ventures, we will continue to analyze the impact of Emmessar Biotech & Nutrition Ltd's ROCE.A ROCE of 12.61% impacts the company's moat – its competitive advantage – in a significant way. A higher ROCE suggests a stronger ability to reinvest profits, innovate, and fend off competition. Conversely, a lower ROCE might indicate difficulties in maintaining market share or generating superior returns. If the ROCE is less than the cost of capital, the company is destroying value. The ability to protect its moat will also impact the Emmessar Biotech & Nutrition share price. It is imperative to track this number over time and adjust for inflation.
This financial analysis is part of a comprehensive 80-parameter fundamental audit of Emmessar Biotech & Nutrition Ltd, verified by Sweta Mishra, and is intended for informational purposes only. The information provided here is observational and should not be construed as a recommendation to buy or sell the company's stock.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Emmessar Biotech & Nutrition Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of EMMESSA across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (59.53%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
10 factors identified
Below-Average Return on Equity (4.23%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Margin Pressure Concerns (-29.14%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Premium Valuation Risk (P/E: 69.37x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-60.71%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-73.53%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-29.08% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-19.73% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-19.73% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Limited Institutional Interest (FII+DII: 0.19%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Emmessar Biotech & Nutrition Ltd Financial Statements
Comprehensive financial data for Emmessar Biotech & Nutrition Ltd including income statement, balance sheet and cash flow
About EMMESSA (Emmessar Biotech & Nutrition Ltd)
Emmessar Biotech & Nutrition Ltd (EMMESSA) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Commodity Chemicals sector with a current market capitalisation of ₹15.95 (Cr). Emmessar Biotech & Nutrition Ltd has delivered a Return on Equity (ROE) of 4.23% and a ROCE of 12.61%. The debt-to-equity ratio stands at 0.00, reflecting the company's capital structure. Investors tracking EMMESSA share price can monitor key metrics including P/E ratio, promoter holding of 59.53%, and quarterly earnings growth.
Company Details
Key Leadership
EMMESSA Share Price: Frequently Asked Questions
What is the current share price of Emmessar Biotech & Nutrition Ltd (EMMESSA)?
As of 17 Feb 2026, 10:09 am IST, Emmessar Biotech & Nutrition Ltd share price is ₹27.02. The EMMESSA stock has a market capitalisation of ₹15.95 (Cr) on NSE/BSE.
Is EMMESSA share price Overvalued or Undervalued?
EMMESSA share price is currently trading at a P/E ratio of 69.37x, compared to the industry average of 20.98x. Based on this relative valuation, the Emmessar Biotech & Nutrition Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of EMMESSA share price?
The 52-week high of EMMESSA share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Emmessar Biotech & Nutrition Ltd share price?
Key factors influencing EMMESSA share price include quarterly earnings growth (Sales Growth: -73.53%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Emmessar Biotech & Nutrition Ltd a good stock for long-term investment?
Emmessar Biotech & Nutrition Ltd shows a 5-year Profit Growth of -19.73% and an ROE of 4.23%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in EMMESSA shares.
How does Emmessar Biotech & Nutrition Ltd compare with its industry peers?
Emmessar Biotech & Nutrition Ltd competes with major peers in the Commodity Chemicals. Investors should compare EMMESSA share price P/E of 69.37x and ROE of 4.23% against the industry averages to determine competitive standing.
What is the P/E ratio of EMMESSA and what does it mean?
EMMESSA share price has a P/E ratio of 69.37x compared to the industry average of 20.98x. Investors pay ₹69 for every ₹1 of annual earnings.
How is EMMESSA performing according to Bull Run's analysis?
EMMESSA has a Bull Run fundamental score of 15.1/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does EMMESSA belong to?
EMMESSA operates in the Commodity Chemicals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Emmessar Biotech & Nutrition Ltd share price.
What is Return on Equity (ROE) and why is it important for EMMESSA?
EMMESSA has an ROE of 4.23%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Emmessar Biotech & Nutrition Ltd generates profits from shareholders capital.
How is EMMESSA debt-to-equity ratio and what does it indicate?
EMMESSA has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is EMMESSA dividend yield and is it a good dividend stock?
EMMESSA offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Emmessar Biotech & Nutrition Ltd shares.
How has EMMESSA share price grown over the past 5 years?
EMMESSA has achieved 5-year growth rates of: Sales Growth -29.08%, Profit Growth -19.73%, and EPS Growth -19.73%.
What is the promoter holding in EMMESSA and why does it matter?
Promoters hold 59.53% of EMMESSA shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Emmessar Biotech & Nutrition Ltd.
What is EMMESSA market capitalisation category?
EMMESSA has a market capitalisation of ₹16 crores, placing it in the Small-cap category.
How volatile is EMMESSA stock?
EMMESSA has a beta of N/A. A beta > 1 suggests the Emmessar Biotech & Nutrition Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is EMMESSA operating profit margin trend?
EMMESSA has a 5-year average Operating Profit Margin (OPM) of -29.14%, indicating the company's operational efficiency.
How is EMMESSA quarterly performance?
Recent quarterly performance shows Emmessar Biotech & Nutrition Ltd YoY Sales Growth of -73.53% and YoY Profit Growth of -60.71%.
What is the institutional holding pattern in EMMESSA?
EMMESSA has FII holding of 0.00% and DII holding of 0.19%. Significant institutional holding often suggests professional confidence in the Emmessar Biotech & Nutrition Ltd stock.